No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis

Abstract

Aim: Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC) in the United States. Achieving sustained viral response with interferon (IFN) treatment reduces the risk from 3%-5% to 0.5%-1% annually. Several studies reported unexpectedly high rates of HCC after treatment with direct-acting antivirals (DAAs). The aim of our study was to compare HCC rates in DAA-, IFN-treated and untreated populations.

Methods: A literature search was conducted using ScienceDirect, Ovid®, Web of Science and MEDLINE through January 2019. Studies were included if they measured rates of de novo or recurrent HCC (following curative treatment) in HCV-infected persons. We included 138 studies (n = 177,512). Simple pooling of data and meta-analysis were performed, using the random effects method.

Results: Mean age was higher in the DAA-treated vs. IFN-treated group (58.4 years vs. 52.6 years; P = 0.0073), as were diabetes prevalence (34.5% vs. 11.7%; P ≤ 0.001) and incident cirrhosis (47.8% vs. 34.2%, P = 0.0017). The incidence rate of de novo HCC was 2.01/100 person-years (py) (95%CI: 1.38, 2.67) in the DAA group and 1.45/100py (95%CI: 0.98, 1.94) in the IFN-treated group. HCC recurred at 16.76/100py (95%CI: 10.75, 22.91) in the DAA-treated group vs. 20.04/100py (95%CI: 2.58, 45.21) after IFN. After adjusting for factors such as age and cirrhosis, the hazard ratio was 0.58 (95%CI: 0.20, 1.07) for HCC occurrence and 0.59 (95%CI: 0.24, 1.03) for HCC recurrence after DAA treatment compared to IFN-based treatment.

Conclusion: We did not find evidence for increased rates of HCC in DAA-treated compared with IFN-treated patients. Compared to those treated with IFN, older patients with additional risk factors for HCC were treated with DAAs. This imbalance appears to explain the higher numerical incidence of HCC among DAA-treated patients.

Keywords

Humans / hepatitis C virus / liver cirrhosis / liver neoplasms / interferons

References

[1] Mittal S.Epidemiology of hepatocellular carcinoma: consider the population..J Clin Gastroenterol2013;47:S2-6 PMCID:PMC3683119

[2] Lemon SM.Is hepatitis C virus carcinogenic?.Gastroenterology2012;142:1274-8 PMCID:PMC4422399

[3] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[4] Hassan MM,Hatten CJ,Li D.Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus..Hepatology2002;36:1206-13

[5] Sanyal AJ,Lencioni R.The Etiology of Hepatocellular Carcinoma and Consequences for Treatment..Oncologist2010;15:14-22

[6] Janjua NZ,Kuo M,Wong J.Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada..J Hepatology2017;66:504-13

[7] Brown JL.Interferon therapy reduces the risk for hepatocellular carcinoma..Gut2000;47:610-1 PMCID:PMC1728124

[8] Ikeda M,Tanaka M,Ide T.Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon..J Gastroenterol2005;40:148-56

[9] Singal AK,Jaganmohan S,Mummadi R.Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus-Related Cirrhosis..Clin Gastroenterol H2010;8:192-9

[10] Fried MW,Reddy KR,Marinos G.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection..N Engl J Med2002;347:975-82

[11] Harris RJ,Griffiths J,Chapman R.Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios..J Hepatol2014;61:530-7

[12] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[13] Kozbial K,Schwarzer R,Al-Zoairy R.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment..J Hepatol2016;65:856-8

[14] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[15] Cardoso H,Rodrigues S,Albuquerque A.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis..J Hepatol2016;65:1070-1

[16] Cheung MC,Hudson BE,McLauchlan J.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis..J Hepatol2016;65:741-7

[17] Zeng QL,Liang HX,Li CX.Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?.J Hepatol2016;65:1068-9

[18] Zavaglia C,Cesarini L,Pontecorvi V.Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?.J Hepatol2017;66:236-7

[19] Nault JC.Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution..J Hepatol2016;65:663-5

[20] Li DK,Fierer DS,Shaikh OS.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study..Hepatology2018;67:2244-53

[21] Kobayashi M,Fujiyama S,Sezaki H.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection..J Med Virol2017;89:476-83

[22] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents..Gastroenterology2017;153:996-1005

[23] Carrat F.Clinical outcomes in HCV-infected patients treated with direct acting antivirals-18 month post-treatment follow-up in the french anrs CO22 hepather cohort study..J Hepatol2016;64:S215

[24] El Kassas M,Salaheldin M,Eltabbakh M.Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis..J Viral Hepat2018;25:623-30

[25] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression..J Hepatol2017;67:1204-12

[26] Pol S.Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma..J Hepatol2016;65:734-40

[27] Butt AS,Abid S.Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?.World J Hepatol2018;10:267-76 PMCID:PMC5838445

[28] Grandhe S.Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection..Gastro Hepat2017;13:421 PMCID:PMC5572972

[29] Romano A,Piovesan S,Cavalletto L.Incidence and pattern of” de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs..In. Hepatology: Wiley-blackwell 111 river st, hoboken 07030-5774, NJ USA;2016;

[30] Renzulli M,Conti F,Serio I.Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis..Eur Radiol2018;28:506-13

[31] Demirjian A,Geschwind JFH,Schutz J.Infiltrating hepatocellular carcinoma: seeing the tree through the forest..J Gastrointest Surg2011;15:2089-97 PMCID:PMC3580771

[32] Zanetto A,Vitale A,Ferrarese A.Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals..Liver Transpl2017;23:1103-12

[33] Fangazio S,Minh MT,Minisini R.Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma..J Hepatol2018;68:212-3

[34] Beste LA,Berry K,Allison SK.Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma..J Hepatol2017;67:32-9 PMCID:PMC6590903

[35] Hengst J,Deterding K,Manns M.DAA-induced HCV clearance does not restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C..J Hepatol2016;64:S417-S8

[36] Tachi Y,Kojima Y,Honda T.Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals..JGH Open2017;1:44-9 PMCID:PMC6207000

[37] Adhoute X,Bourlière M.Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma..Transl Gastroenterol Hepatol2017;2:110 PMCID:PMC5762991

[38] Belli LS,Cortesi PA,Rockenschaub SR.Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study..J Hepatol2016;65:524-31

[39] Munoz SJ,Rothstein KD,Patel V.Curing decompensated wait listed HCV patients with the new DAAs: the potential significant impact on liver transplant wait list and organ allocation..Hepatology2015;62:311A

[40] Manns M,Gane EJ,McCaughan G.Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial..Lancet Infect Dis2016;16:685-97

[41] Poordad F,Vierling JM,Fontana RJ.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence..Hepatology2016;63:1493-505 PMCID:PMC5069651

[42] Jacobson I,Firpi-Morell R,Verna E.O008: Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-pugh class B cirrhosis (C-salt part A)..J Hepatol2015;62:S193-S4

[43] Curry MP,Bzowej N,Korenblat KM.Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis..N Engl J Med2015;373:2618-28

[44] Aqel BA,Leise M,Chervenak AE.Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis..Hepatology2015;62:1004-12

[45] Deuffic-Burban S,Rosa I,Cannesson A.Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach..Digest Liver Dis2014;46:157-63

[46] Ponziani FR,Binda C,Siciliano M.Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C..World J Hepatol2017;9:352-67 PMCID:PMC5340991

[47] Chan K,Groessl EJ,Wong JB.Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration..Clin Gastroenterol Hepatol2013;11:1503-10

[48] He T,Hur C.Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6..Aliment Pharmacol Ther2017;46:711-21

[49] Chhatwal J,Lopez-Olivo MA.Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals..Pharmacoeconomics2016;34:551-67